PIDILITIND – Pidilite Industries – Q4 FY26 Financial Results – 7-May-26

Pidilite’s FY26 strong: PAT +17.9%, 28.1% EBITDA margins, near‑zero debt, 90%+ FCF conversion. C&B compounding with leverage visible. Risks: DSO >54 days, dividend payout limiting reinvestment, CWIP doubling pressuring FCF if revenue lags. High‑quality compounder; valuation, not business quality, is the debate for FY27.

4–6 minutes


🔍 Observations

Topline

  • Revenue from operations grew 11.1% YoY (₹13,140 Cr → ₹14,601 Cr), driven by volume-led expansion across both segments; C&B outpaced B2B at 11.4% vs 7.2%.
  • Q4FY26 revenue at ₹3,583 Cr grew 14.1% YoY over Q4FY25 (₹3,141 Cr), but declined 3.4% QoQ from Q3FY26 (₹3,710 Cr) — typical seasonal softness.
  • Inter-segment eliminations narrowed significantly (₹303 Cr → ₹245 Cr), indicating reduced internal trade, with external revenue quality improving.

Bottomline

  • PAT grew 17.9% YoY (₹2,096 Cr → ₹2,471 Cr), ahead of revenue growth — operating leverage is visible at scale.
  • Exceptional items dropped sharply to ₹13.7 Cr (FY26) from ₹24.9 Cr (FY25), meaning clean earnings quality improved further.
  • Effective tax rate held steady at ~25.4%, with minimal deferred tax drag — no tax-driven PAT distortion.

Margins

  • EBITDA margin expanded 131 bps to 28.1% — raw material intensity stable, while employee and other expense leverage improved.
  • PAT margin (consolidated) widened 98 bps to 16.93% — bottom-line efficiency compounding quietly.
  • B2B segment EBIT margin: ₹529 Cr on ₹3,211 Cr revenue = 16.5% vs C&B at ₹3,546 Cr on ₹11,574 Cr = 30.6%; structural margin gap between segments is wide and persists.

Growth Trajectory

  • Three-year PAT CAGR implied by FY25→FY26 base: 17.9% single-year step is strong; C&B segment profit grew 19% YoY, signaling consumer-facing pricing power is intact.
  • OCF grew 24.1% YoY (₹2,287 Cr → ₹2,837 Cr), faster than PAT — cash conversion ratio improved to 1.15x from 1.09x.
  • CWIP jumped from ₹129 Cr to ₹329 Cr — accelerating capex cycle signals capacity expansion ahead; sustaining margins through this investment phase is the key test.



🧮 Profit & Loss Statement


🧮 Balance Sheet


🧮 Cash Flows Statement


🟢 Green Flags

  • OCF/FCF conversion is best-in-class: FCF of ₹2,244 Cr against PAT of ₹2,471 Cr = 90.8% conversion; cash earnings are real.
  • C&B segment margin at 30.6% reflects pricing power in branded adhesives/construction chemicals — structurally defensible moat.
  • Near-zero leverage: Total borrowings of ₹106 Cr against equity of ₹11,049 Cr; D/E at 0.01x — balance sheet is fortress-grade.
  • Inventory efficiency improving: DIO fell from 46.9 days to 43.4 days — working capital optimization despite volume growth.
  • ROE expanded to 22.83% (from 21.95%) without leverage — quality return, not financial engineering.
  • Bonus share issuance (1:1, Sep 2025) signals board confidence; EPS adjusted to ₹24.07 (basic), still grew 17.9% YoY on restated basis.
  • Current ratio at 2.38x with liquid investments of ₹3,920 Cr in current assets — short-term resilience is exceptional.

🔴 Red Flags

  • DSO deteriorated to 54.5 days from 50.3 days — receivables grew ₹370 Cr vs revenue growth of ₹1,461 Cr; collections are not keeping pace with revenue scaling.
  • Dividend payout ratio spiked to 89.3% (FY26) from 49% (FY25) — includes final + interim payout of ₹21.50/share; at this level, reinvestment capacity is being stretched.
  • Financing outflow surged to ₹1,671 Cr (from ₹918 Cr in FY25) primarily on dividends (₹1,526 Cr total paid) — aggressive capital return could constrain future strategic flexibility.
  • B2B segment growing slowly at 7.2% revenue, 8.2% profit — industrial adhesives/resins segment is not a growth engine; concentration risk if C&B momentum slows.
  • Others segment turned loss-making at ₹(9.3) Cr EBIT vs ₹0.9 Cr in FY25 — NBFC operations and raw material sales are dilutive to consolidated margins.
  • CWIP more than doubled to ₹329 Cr — capex acceleration without clear revenue visibility could pressure near-term FCF if utilisation lags.
  • Goodwill + intangibles at ₹2,843 Cr = 18.4% of total assets — impairment risk warrants monitoring, especially with associates already flagged as exceptional items.

📊 Balance Sheet Analysis

  • Asset-light growth: Total assets grew 10.1% to ₹15,433 Cr while equity grew 10.9% — asset efficiency maintained; equity multiplier stable at 1.40x.
  • Liquid investment book of ₹3,920 Cr in current investments provides substantial hidden liquidity beyond reported cash of ₹232 Cr.
  • Deferred tax liabilities (₹413 Cr) are material but stable — not a near-term cash risk; no aggressive tax structuring signals.
  • Trade payables (₹1,537 Cr, DPO 99.7 days) are stretched — working capital funded partly by supplier credit; sustainable given Pidilite’s procurement scale, but bears watching.

💰 Cash Flow Analysis

  • OCF of ₹2,837 Cr comfortably covered capex of ₹593 Cr and dividends of ₹1,526 Cr — cash generation is self-funding all capital allocation.
  • Gross investment churn (purchases ₹6,388 Cr, proceeds ₹5,831 Cr) reflects active treasury management of liquid surplus, not operational capex — net investing outflow of ₹1,236 Cr is clean.
  • Working capital consumed ₹43 Cr net (vs operating profit of ₹3,742 Cr pre-WC) — exceptional conversion; receivable buildup is the sole drag.
  • Net cash declined ₹71 Cr to ₹218 Cr — but liquid investments grew ₹758 Cr to ₹3,920 Cr; headline cash decline is misleading.

💡 Investment Outlook

Pidilite enters FY27 with the strongest earnings quality it has demonstrated in recent years — 17.9% PAT growth, 28.1% EBITDA margins, near-zero debt, and 90%+ FCF conversion leave little structural to fault.

The core C&B franchise continues to compound ahead of top-line, with margin expansion suggesting operating leverage is real.

Key monitorables are the DSO deterioration (now above 54 days), a dividend payout that leaves thin reinvestment headroom, and whether the accelerating capex cycle (CWIP doubling) translates to revenue before it pressures FCF.

At current fundamentals, this is a high-quality compounder — the question is entirely one of valuation, not business quality.


Disclaimer: This post features ChartAlert-AI-generated financial content which may contain inaccuracies or errors. This commentary is strictly for informational purposes and does not constitute a recommendation to buy or sell any security. Investors are responsible for performing their own due diligence; always consult with a licensed financial advisor before making investment decisions.


Discover more from ChartAlert®

Subscribe now to keep reading and get access to the full archive.

Continue reading

Discover more from ChartAlert®

Subscribe now to keep reading and get access to the full archive.

Continue reading